On February 7, 2013, Avanir Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the three months ended December 31, 2012 (the "Earnings Press Release"). A copy of the Earnings Press Release is furnished herewith as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

On February 7, 2013, the Company issued a press release announcing positive interim data from the pharmacokinetic study with AVP-786 (the "Press Release"). A copy of the Press Release is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

(d) Exhibits

           Exhibit No.   Description

           99.1          Earnings Press Release, dated February 7, 2013

           99.2          Press Release, dated February 7, 2013

* * *